One misplaced decimal point in an SmPC - and a batch worth 2 million euros gets pulled from the market. This isn’t a hypothetical scenario: according to IntuitionLabs, translation errors in pharmaceutical documentation are a real cause of drug recalls in the EU. And FDA data shows that over 50% of product recalls are linked to labeling and packaging errors. If you’re working in pharmaceutical translation or planning to enter this market - let’s break down which documents need translating for EMA and FDA, what the quality requirements are, and how much it all costs.
Which Documents Need Translation for Drug Registration¶
A pharmaceutical registration dossier isn’t a single document - it’s a massive package of dozens or even hundreds of files. The translation scope depends on the regulatory pathway (EMA centralized procedure, national, FDA submission) and target markets. But there’s a core set of documents that comes up in virtually every case.
Common Technical Document (CTD) - the Foundation of Every Dossier¶
CTD is the standardized format for submitting registration materials, developed by ICH (International Council for Harmonisation). It’s used by EMA, FDA, and regulators in Japan, Canada, Australia, and dozens of other countries. The CTD structure has five modules:
| Module | Content | Translation needed? |
|---|---|---|
| Module 1 | Administrative info, patient information (SmPC, PIL, labelling) | Yes - in the language of every country where the drug is sold |
| Module 2 | Overviews and summaries of Modules 3-5 | Partially - depends on the regulator |
| Module 3 | Quality (pharmaceutical documentation, CMC) | Rarely - usually in English |
| Module 4 | Non-clinical studies (pharmacology, toxicology) | Rarely - usually in English |
| Module 5 | Clinical studies | Rarely - usually in English |
Here’s the key: Modules 2-5 are typically submitted in English and don’t require translation. Module 1 is where translation becomes critical and mandatory. That’s where you’ll find the SmPC, Package Leaflet (PIL), and labelling texts - the documents that directly affect patient safety.
Documents for EMA (European Union)¶
If a drug goes through the EMA centralized procedure, it needs translation into all official EU languages plus Norwegian and Icelandic (for the EEA):
- SmPC (Summary of Product Characteristics) - the product profile for doctors and pharmacists. It’s the core regulatory document that drives prescribing decisions
- PIL (Package Information Leaflet) - the patient leaflet, that folded piece of paper inside every medicine box
- Labelling - text on the outer and inner packaging
- Annex II - conditions of the marketing authorization
- Conditions or restrictions regarding safe and effective use
That’s 24 official EU languages (Bulgarian, Croatian, Czech, Danish, Dutch, Estonian, Finnish, French, German, Greek, Hungarian, Irish, Italian, Latvian, Lithuanian, Maltese, Polish, Portuguese, Romanian, Slovak, Slovenian, Spanish, Swedish, and English) plus Norwegian and Icelandic. A total of 26 language versions of each document.
As stated by EMA:
The marketing authorisation holder shall submit annotated translations in all EU languages to member state competent authorities. National authorities then have 14 calendar days to conduct their linguistic review and return feedback.
In plain English: after the committee issues a positive opinion, you have exactly 5 days to submit translations in all 26 languages. Then national regulators get 14 days for their linguistic review, and you get another 5 days to incorporate their feedback. The pace is brutal - and if translations aren’t ready on time, the entire registration gets delayed.
Documents for FDA (United States)¶
The FDA takes a fundamentally different approach: all submissions must be in English. If original documents (for example, clinical trial results from another country) are in a different language - you need a full certified English translation.
According to 21 CFR 314.50:
The applicant must submit an accurate and complete English translation of each part of the application that is not in English, along with a copy of each original literature publication.
Documents that need translation for FDA: - NDA (New Drug Application) or ANDA (Abbreviated NDA) - if the original isn’t in English - Clinical data from studies conducted outside the US - Labelling for the US market (FDA Prescribing Information, Patient Package Insert, Medication Guide) - Informed Consent Forms for clinical trials - IND (Investigational New Drug) materials
A separate topic is linguistic validation for Patient-Reported Outcomes (PRO). If a clinical study uses quality-of-life or symptom questionnaires, the FDA requires translations to undergo linguistic validation: forward translation → back translation → cognitive debriefing with patients → final version. It’s a separate and expensive process.
Other Regulators¶
Beyond EMA and FDA, there are dozens of other regulatory bodies with their own language requirements:
| Regulator | Country | Submission language |
|---|---|---|
| PMDA | Japan | Japanese mandatory |
| NMPA | China | Chinese mandatory |
| Health Canada | Canada | English + French |
| TGA | Australia | English |
| ANVISA | Brazil | Portuguese |
| COFEPRIS | Mexico | Spanish |
When a pharma company launches a drug across multiple markets simultaneously - the translation volume becomes staggering. A single registration dossier can contain tens of thousands of pages, and each market needs its own adapted version.
Quality Requirements for Pharmaceutical Translation¶
Pharmaceutical translation isn’t simply swapping words from one language to another. The standards here are far stricter than in most other translation fields.
EMA’s QRD Templates¶
For translating SmPC, PIL, and labelling in the EU, you’ll work with QRD templates (Quality Review of Documents). These are standardized templates available in all 24 EU languages that specify:
- The exact document structure (headings, sections, subsections)
- Font and formatting
- Standard wording - many phrases are pre-translated and must be used verbatim
- Black triangle (▼) requirements for products under additional monitoring
- Pharmacovigilance contact information for each country
Pro tip: the QRD template isn’t a suggestion - it’s a mandatory requirement. If your translation doesn’t match the template, it’ll be sent back for revision, delaying the entire procedure. Always download the current template version from the EMA website before starting work.
ISO 17100 and Pharma-Specific Requirements¶
The baseline standard for translation services is ISO 17100, which requires at minimum two qualified professionals (translator + reviser). But for pharma, that’s often not enough. Additional requirements include:
- SME review (Subject Matter Expert) - beyond linguistic review, the translation must be checked by a domain expert (pharmacist, physician, regulatory specialist)
- Terminology validation - using approved glossaries and term bases (MedDRA, INN, pharmacopoeial nomenclature)
- Number, unit, and dosage verification - a separate QA step, because a dosage error can be fatal
- Back translation - reverse translation for accuracy verification (FDA requirement for PRO instruments)
- Audit trail - complete documentation of the translation process (who translated, who reviewed, what changes were made)
Pharma regulatory translation requires additional safeguards including subject-matter expertise verification, terminology validation against approved glossaries, and format-specific quality checks.
This means a standard translator with medical specialization isn’t always sufficient. You need someone who understands the regulatory context, knows QRD templates, and has hands-on experience with pharmaceutical submissions specifically.
What You Need to Know About MedDRA Terms¶
MedDRA (Medical Dictionary for Regulatory Activities) is the standardized medical terminology dictionary used for coding adverse events and medical occurrences. Both EMA and FDA require MedDRA usage in pharmacovigilance. A translator working with ICSRs (Individual Case Safety Reports) or PSURs (Periodic Safety Update Reports) needs to know MedDRA coding and use the approved terms in each language.
Pharmacovigilance: Translation After Registration¶
Drug registration isn’t the end of translation work - it’s more like the beginning. Once a medicine hits the market, pharmacovigilance kicks in - monitoring the drug’s safety throughout its entire lifecycle. And the translation volume here often exceeds the registration phase.
Pharmacovigilance Documents¶
| Document | What it is | Translation requirements |
|---|---|---|
| ICSR (Individual Case Safety Report) | Report on an individual adverse event case | Verbatim or accurate translation from the source language |
| PSUR (Periodic Safety Update Report) | Periodic safety information update report | English for EMA single assessment |
| RMP (Risk Management Plan) | Risk management plan | English + language versions for patient materials |
| DHPC (Dear Healthcare Professional Communication) | Letters to doctors about new safety information | All languages of countries where the drug is sold |
| SmPC/PIL updates | Changes to product characteristics or patient leaflet | All 24+ EU languages |
According to EMA’s GVP guidelines, ICSRs must contain either the verbatim text from the primary source or an accurate translation. If a patient reports an adverse event in Finnish - it needs to be accurately translated into English for submission to the EudraVigilance database.
Critical detail: for DHPCs (urgent safety communications to healthcare professionals), timelines are even tighter - often 24-48 hours for translation and distribution. Pharma companies need a network of vetted translators ready to work on emergency timelines.
Submission Timelines: Why Time is Everything¶
Pharmaceutical translation is always a race against the clock. Regulators set strict deadlines, and missing them can delay a drug’s market launch by months.
EMA Timeline (Centralized Procedure)¶
- Day 215: submit SmPC/PIL/Labelling translations along with QRD Form 1
- Day 5 post-opinion: annotated translations in all EU languages submitted to national regulators
- 14 days: national authorities conduct linguistic review and return comments
- 5 days: final translations incorporating review comments
In practical terms: you need 26 language versions of the SmPC (often 15-30 pages each), PIL (4-8 pages), and labelling - ready and verified within 5 days. That’s hundreds of pages of precise pharmaceutical translation under extreme time pressure.
FDA Timeline¶
The FDA doesn’t formally impose such tight translation deadlines, since all submissions are in English anyway. But if you’re filing clinical study results from other countries - the translation must be ready by the NDA/BLA submission date. In practice, big pharma companies start translating clinical reports 6-12 months before the planned submission.
For linguistic validation of PRO instruments, timelines are even longer - the full process (translation → back translation → cognitive debriefing → finalization) takes 3-6 months.
How Much Does Pharmaceutical Translation Cost¶
Pharmaceutical regulatory translation is one of the most expensive segments of the translation market. And rightfully so: an error in dosage or contraindications can cost lives.
Per-Word Pricing¶
| Document type | Price per word (USD) | Notes |
|---|---|---|
| SmPC / PIL / labelling | $0.20 - $0.40 | Regulatory translation with QRD template |
| Clinical protocols and reports | $0.25 - $0.50 | Complex terminology, large volumes |
| ICSR / pharmacovigilance | $0.20 - $0.35 | Urgency and MedDRA coding |
| Linguistic validation (PRO) | $5,000 - $15,000 per language | Full cycle: translation + back translation + cognitive debriefing |
| Marketing materials | $0.15 - $0.30 | Less regulated but with medical terminology |
According to Circle Translations, regulatory submissions run $0.25-$0.50 per word - that’s 2-5x more expensive than standard commercial translation.
Let’s do the math for a typical project: SmPC at 20 pages (~7,000 words) × 26 languages × $0.30 per word = $54,600 for the SmPC alone. Add PIL and labelling - and the budget easily crosses $100,000 per drug.
Why So Expensive¶
- Translator qualifications: you need people with pharmaceutical or medical degrees and regulatory document experience
- Multi-level QA: translator → reviser → SME → project manager → QRD compliance check
- Urgency: 5 days for 26 languages means a large team working in parallel
- Liability: an error can lead to drug recalls, lawsuits, and millions in damages
- Tools: specialized pharma translation software (Veeva Vault, XTRF, memoQ with pharma modules)
If you’re a translator looking to work in this niche - rates are significantly higher than general translation, but the entry barrier matches. You need experience, certifications, and a flawless track record.
Common Mistakes and How to Avoid Them¶
According to IntuitionLabs, SmPC translation errors can lead to drug recalls, fines, and even criminal liability. Here are the most common issues:
1. Numerical Data Errors¶
Incorrectly translated decimal points/commas (Europe uses commas, the US uses periods), wrong units of measurement (mg instead of mcg), missing leading zeros before decimal points. In 2025, Aurobindo Pharma USA recalled 7,440 bottles of Ibuprofen oral suspension due to a labeling error.
How to avoid it: a dedicated QA step just for numerical data and dosages. Two people independently verify every single number.
2. QRD Template Non-Compliance¶
Using your own wording instead of the standard phrases from QRD templates. For example, the phrase “If you get any side effects” has an approved translation in every language, and any deviation is grounds for document rejection.
How to avoid it: always start with the current QRD template and only fill in the variable sections.
3. Inconsistency Across Language Versions¶
Different translations of the same term across language versions. Or different content - where one language version contains information that’s missing from another.
How to avoid it: a centralized terminology database (Translation Memory + Termbase), one project manager for all languages, cross-reference checks between versions.
4. Ignoring Local Requirements¶
Each EU country may have additional labelling content requirements. For instance, Braille marking is mandatory in the EU for outer packaging. Some countries require additional warnings or different pharmacovigilance contact information.
How to avoid it: a local requirements checklist for each country, consultation with regulatory specialists in the target market.
5. Confidentiality Issues¶
Pharmaceutical data is trade secret territory. Leaking information about a new drug before registration can cost a company billions. Using free AI translators or cloud services for pharmaceutical documents is a serious confidentiality risk.
How to avoid it: only vetted providers with NDAs, on-premise or private cloud solutions, GDPR compliance for European data.
The Role of AI in Pharmaceutical Translation¶
AI translation is evolving rapidly, but the pharmaceutical industry remains one of the most conservative when it comes to adoption. And for good reason.
Where AI Already Works¶
- First drafts for large volumes (clinical reports, internal documentation) with mandatory post-editing
- Terminology search and consistency checking
- QA checks - automatic detection of numerical discrepancies, missing segments, inconsistencies between language versions
- Pre-formatting to QRD templates
If you need a quick translation of an internal clinical report for review - AI tools like ChatsControl can speed things up significantly. Upload the document, get a quality draft in minutes, then have a specialist do the revision. It saves hours on routine documents.
Where AI Can’t Replace Humans¶
- Regulatory submissions (SmPC, PIL, labelling) - human translation with multi-level QA only
- Linguistic validation - requires cognitive debriefing with real patients
- ICSRs and pharmacovigilance - accuracy requirements are too high
- Legally binding documents - AI can’t bear legal responsibility
As experts note, both EMA and FDA require full documentation of the translation process - who translated, who reviewed, what qualifications the translator holds. “AI did it” doesn’t meet the documentation standard that regulators expect.
The AI hallucination problem is especially critical in pharma texts: a fabricated side effect, a “creatively reinterpreted” dosage, or a missing contraindication is a direct threat to patient health.
How to Break Into the Pharmaceutical Translation Niche¶
If you’re a translator looking to work with pharmaceutical documents - this is one of the most lucrative niches out there. But also one of the most demanding in terms of qualifications.
What You Need¶
- Education: pharmaceutical, medical, or biological science degree. Or a specialized master’s in medical translation
- Regulatory procedure knowledge: EMA centralized procedure, FDA submission process, ICH guidelines
- QRD template experience: hands-on experience translating SmPC/PIL using QRD templates
- MedDRA knowledge: ability to work with the Medical Dictionary for Regulatory Activities
- CAT tools: experience with memoQ, Trados, or other CAT systems (preferably with pharma modules)
- Certifications: ISO 17100, ATA certification - a major plus
Rates in pharmaceutical translation range from $0.15 to $0.35 per word for freelancers - significantly higher than general or even legal translation. For comparison, standard document translation runs $0.08-$0.12 per word.
Where to find clients: - CROs (Contract Research Organizations) - companies running clinical trials - Pharma companies - large (Novartis, Roche, Pfizer) and mid-size - Regulatory consultancies - firms that prepare registration dossiers - Specialized translation agencies - Lionbridge, TransPerfect, RWS all have dedicated pharma divisions
FAQ¶
Do I need to translate the entire registration dossier into 24 EU languages?¶
No, not everything. Modules 2-5 of the CTD (quality, non-clinical, clinical) are usually submitted in English. Mandatory translation into all languages is required for Module 1: SmPC, PIL, and labelling. These are the documents directly used by doctors and patients.
How much does a full set of translations for EU registration cost?¶
It depends on documentation volume and the number of languages. For a typical drug with a 20-page SmPC, 6-page PIL, and labelling - the budget for 26 language versions starts at $80,000-$150,000. For complex biologics with extensive SmPCs, the figure can reach $200,000+.
Can AI fully replace humans in pharmaceutical translation?¶
Not today. Both EMA and FDA require process documentation specifying the qualifications of the translator and reviser. AI can be used for first drafts or QA checks, but the final translation of regulatory documents must be performed and reviewed by qualified humans.
What’s the difference between pharmaceutical and medical translation?¶
Medical translation is a broader category that includes discharge summaries, diagnoses, and medical certificates. Pharmaceutical translation is a specialized subset dealing with drug registration, clinical trials, and pharmacovigilance. Requirements are significantly stricter: QRD templates, MedDRA, ICH guidelines, audit trails.
How long does it take to translate an SmPC into 26 EU languages?¶
Under the EMA centralized procedure, you have 5 days post-opinion to submit translations. In practice, preparation starts 2-4 weeks before the expected opinion. Work runs in parallel across 26 translation teams, making it one of the most intensive processes in the translation industry.